Rodger Novak
2016
In 2016, Rodger Novak earned a total compensation of $6.4M as Chief Executive Officer at CRISPR Therapeutics AG, a 277% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $235,940 |
|---|---|
| Option Awards | $1,971,400 |
| Salary | $436,888 |
| Stock Awards | $3,674,722 |
| Other | $38,930 |
| Total | $6,357,880 |
Novak received $3.7M in stock awards, accounting for 58% of the total pay in 2016.
Novak also received $235.9K in non-equity incentive plan, $2M in option awards, $436.9K in salary and $38.9K in other compensation.
Rankings
In 2016, Rodger Novak's compensation ranked 1,097th out of 14,075 executives tracked by ExecPay. In other words, Novak earned more than 92.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,097 out of 14,075 | 92nd |
Division Manufacturing | 370 out of 5,489 | 93rd |
Major group Chemicals And Allied Products | 98 out of 1,895 | 95th |
Industry group Drugs | 64 out of 1,538 | 96th |
Industry Biological Products, Except Diagnostic Substances | 11 out of 279 | 96th |
Source: SEC filing on April 18, 2017.
Novak's colleagues
We found three more compensation records of executives who worked with Rodger Novak at CRISPR Therapeutics AG in 2016.